在拿到第一个“十亿美元分子”之后,百济神州还想要第二个。文|《中国企业家》记者 谭丽平编辑|张昊图片来源|视觉中国国产创新药在海外市场又迎来商业化的新突破。10月初,百济神州最核心的抗癌产品——PD-1(替雷利珠单抗)在美国正式商业化上市,用于治疗既往接受过系统化疗后的一些成人癌症患者。该药在今年3月获得美国FDA(食品药品监督管理局)批准,百济神州花了半年时间,在美国自建了商业化团队。这是它进军...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.